C-Rad Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de C-Rad de 34.7% y 14.8% por año respectivamente. Se prevé que el BPA crezca en un 34.8% al año. Se espera que la rentabilidad financiera sea de 24.5% en 3 años.

Información clave

34.7%

Tasa de crecimiento de los beneficios

34.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	36.9%
Tasa de crecimiento de los ingresos	14.8%
Rentabilidad financiera futura	24.5%
Cobertura de analistas	Low
Última actualización	22 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Sentiment Still Eluding C-Rad AB (publ) (STO:CRAD B)

Oct 24

Market Participants Recognise C-Rad AB (publ)'s (STO:CRAD B) Earnings Pushing Shares 29% Higher

Jun 02

Earnings Miss: C-Rad AB (publ) Missed EPS By 5.5% And Analysts Are Revising Their Forecasts

Jan 30

C-Rad (STO:CRAD B) Shareholders Will Want The ROCE Trajectory To Continue

Jul 03

Will the Promising Trends At C-Rad (STO:CRAD B) Continue?

Mar 05

Are C-Rad's (STO:CRAD B) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 07

What Percentage Of C-Rad AB (publ) (STO:CRAD B) Shares Do Insiders Own?

Jan 17

Previsiones de crecimiento de beneficios e ingresos

OM:CRAD B - Estimaciones futuras de los analistas y datos financieros pasados (SEK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	679	121	87	N/A	1
12/31/2025	598	89	60	N/A	1
12/31/2024	517	61	46	N/A	1
9/30/2024	486	58	38	48	N/A
6/30/2024	497	54	68	81	N/A
3/31/2024	458	48	47	62	N/A
12/31/2023	425	36	16	33	N/A
9/30/2023	385	24	-3	14	N/A
6/30/2023	357	20	-27	-13	N/A
3/31/2023	329	12	-11	3	N/A
12/31/2022	301	7	-2	10	N/A
9/30/2022	280	14	-16	-9	N/A
6/30/2022	260	12	-6	1	N/A
3/31/2022	257	21	6	12	N/A
12/31/2021	261	25	12	18	N/A
9/30/2021	258	26	16	23	N/A
6/30/2021	247	25	30	36	N/A
3/31/2021	230	17	26	32	N/A
12/31/2020	222	14	12	18	N/A
9/30/2020	198	-11	2	9	N/A
6/30/2020	201	-16	-13	-4	N/A
3/31/2020	210	-14	-19	-7	N/A
12/31/2019	205	-14	5	16	N/A
9/30/2019	212	23	-4	5	N/A
6/30/2019	203	24	7	14	N/A
3/31/2019	204	27	9	13	N/A
12/31/2018	190	21	-14	-10	N/A
9/30/2018	174	-2	-11	-8	N/A
6/30/2018	161	-4	N/A	-6	N/A
3/31/2018	141	-10	N/A	-13	N/A
12/31/2017	133	-11	N/A	-4	N/A
9/30/2017	118	-16	N/A	-12	N/A
6/30/2017	108	-23	N/A	-36	N/A
3/31/2017	90	-28	N/A	-37	N/A
12/31/2016	83	-31	N/A	-45	N/A
9/30/2016	74	-33	N/A	-40	N/A
6/30/2016	70	-32	N/A	-31	N/A
3/31/2016	73	-27	N/A	-27	N/A
12/31/2015	73	-21	N/A	-23	N/A
9/30/2015	73	-20	N/A	-19	N/A
6/30/2015	66	-16	N/A	-19	N/A
3/31/2015	62	-8	N/A	-14	N/A
12/31/2014	57	-7	N/A	-13	N/A
9/30/2014	56	-5	N/A	-8	N/A
6/30/2014	59	-4	N/A	-12	N/A
3/31/2014	52	-17	N/A	-29	N/A
12/31/2013	49	-21	N/A	-23	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (34.7% al año) de CRAD B es superior a la tasa de ahorro (1.2%).

Beneficios vs. Mercado: Se prevé que los beneficios (34.7% al año) de CRAD B crezcan más rápidamente que el mercado Swedish (15% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de CRAD B crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (14.8% al año) de CRAD B crezcan más rápidamente que los del mercado Swedish (0% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 14.8% al año) de CRAD B crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de CRAD B sea alta dentro de 3 años (24.5%)

C-Rad Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 14% to kr49.00

Price target increased by 12% to kr58.00

Consensus EPS estimates fall by 11%, revenue upgraded

Price target increased by 13% to kr65.50

Consensus EPS estimates fall by 14%

Price target decreased by 11% to kr57.75

Recent updates

C-Rad AB (publ) to Report Q3, 2025 Results on Oct 23, 2025

Independent Director recently bought kr190k worth of stock

Price target decreased by 14% to kr49.00

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Sentiment Still Eluding C-Rad AB (publ) (STO:CRAD B)

CEO & President recently bought kr85k worth of stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Market Participants Recognise C-Rad AB (publ)'s (STO:CRAD B) Earnings Pushing Shares 29% Higher

Investor sentiment improves as stock rises 16%

C-Rad AB (publ) Appoints Mats Thorén as Board Member

Full year 2023 earnings: EPS and revenues exceed analyst expectations

C-Rad AB (publ) to Report Fiscal Year 2023 Results on Apr 23, 2024

Returns On Capital Are A Standout For C-Rad (STO:CRAD B)

C-Rad's (STO:CRAD B) Earnings Are Weaker Than They Seem

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Do C-Rad's (STO:CRAD B) Earnings Warrant Your Attention?

Price target increased by 12% to kr58.00

C-Rad AB (publ)'s (STO:CRAD B) Popularity With Investors Is Clear

C-Rad AB (publ) to Report Q3, 2024 Results on Oct 23, 2024

Consensus EPS estimates fall by 11%, revenue upgraded

Price target increased by 13% to kr65.50

Third quarter 2023 earnings: Revenues exceed analyst expectations

Is Now The Time To Look At Buying C-Rad AB (publ) (STO:CRAD B)?

Investor sentiment improves as stock rises 19%

Returns Are Gaining Momentum At C-Rad (STO:CRAD B)

C-Rad AB (Publ) Announces Former Employee Appeals Verdict from the Patent and Market Court of Appeal

Consensus EPS estimates fall by 14%

New major risk - Earnings quality

C-Rad AB (publ) to Demonstrate Enhancements in Surface Guided Solutions for Advanced Radiotherapy Treatments at AAPM

Second quarter 2023 earnings: Revenues exceed analyst expectations

Less than half of directors are independent

Price target decreased by 11% to kr57.75

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

C-Rad AB (publ) to Report Fiscal Year 2022 Final Results on Apr 06, 2023

C-Rad AB (Publ) Appoints Christoffer Herou as CFO

C-Rad AB (Publ) Announces CEO Changes

Are Investors Undervaluing C-Rad AB (publ) (STO:CRAD B) By 45%?

Price target decreased to kr62.50

C-Rad AB (publ) Announces CFO Changes

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analyst expectations

C-Rad AB (publ) to Report Fiscal Year 2023 Results on Feb 02, 2024

Price target decreased to kr62.50

C-RAD Launches New Updated eDucation Portal as an Online Platform

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analyst expectations

Is Now An Opportune Moment To Examine C-Rad AB (publ) (STO:CRAD B)?

Henrik Bergentoft Resigns as CFO of C-RAD

C-Rad Announces CEO Changes

Chief Financial Officer recently bought kr93k worth of stock

Consensus EPS estimates fall by 41%

Price target decreased to kr72.50

First quarter 2022 earnings: Revenues miss analyst expectations

Returns Are Gaining Momentum At C-Rad (STO:CRAD B)

Insufficient new directors

Insufficient new directors

Earnings Miss: C-Rad AB (publ) Missed EPS By 5.5% And Analysts Are Revising Their Forecasts

Full year 2021 earnings: EPS and revenues miss analyst expectations

C-Rad AB (publ) to Report Q3, 2022 Results on Oct 28, 2022

Price target increased to kr82.00

C-Rad Achieves Another Milestone Ensuring the Availability of SGRT, the Standard of Care for Radiotherapy

Third quarter 2021 earnings released

Chief Operating Officer recently sold kr625k worth of stock

Second quarter 2021 earnings released

C-Rad (STO:CRAD B) Shareholders Will Want The ROCE Trajectory To Continue

C-Rad AB (publ) Announces The Patent and Market Court Rejected Former Employee Claim for Compensation

The Patent and Market Court of Appeal Issues Judgement Confirming C-Rad's Entitlement to Beamocular's Invention

Full year 2020 earnings released: EPS kr0.43 (vs kr0.45 loss in FY 2019)